Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices 50171 

hear arguments from the parties or other 

interested persons with respect to the 

public interest in this investigation, as 

appropriate, and provide the 

Commission with findings of fact and a 

recommended determination on this 

issue, which shall be limited to the 

statutory public interest factors set forth 

in 19 U.S.C. l337(d)(l), (f)(1), (g)(1); 

(4) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainant is: Sonrai 

Memory Ltd., Suite 23, The Hyde 

Building, Carrickmines, Dublin 18, 

Ireland. 

(b) The respondents are the following 

entities alleged to be in violation of 

section 337, and are the parties upon 

which the complaint is to be served: 

Amazon.Com, Inc., 410 Terry Avenue 

North, Seattle, WA 98109 

Dell Technologies Inc., One Dell Way, 

Round Rock, TX 78682 

EMC Corporation, One Dell Way, Round 

Rock, TX 78682 

Lenovo Group Ltd., 6 Chuang ye Road, 

Haidian District, Beijing 100085, 

China 

Lenovo (United States) Inc., 1009 Think 

Place, Building One, Morrisville, NC 

27560 

Motorola Mobility LLC, 222 W 

Merchandise Mart Plaza, Suite 1800, 

Chicago, IL 60654 

LG Electronics Inc., LG Twin Tower 128 

Yeoui-daero, Yeongdeungpo-gu, 

Seoul, 07336, South Korea 

LG Electronics USA, Inc., 1000 Sylvan 

Ave., Englewood Cliffs, NJ 07632 

Samsung Electronics Co., Ltd., 129 

Samsung-Ro, Maetan-3dong, 

Yeongtong-gu, Suwon-si, Gyeonggido, 443–742, South Korea 

Samsung Electronics America, Inc., 85 

Challenger Rd., Ridgefield Park, NJ 

07660 

(c) The Office of Unfair Import 

Investigations, U.S. International Trade 

Commission, 500 E Street SW, Suite 

401, Washington, DC 20436; and 

(5) For the investigation so instituted, 

the Chief Administrative Law Judge, 

U.S. International Trade Commission, 

shall designate the presiding 

Administrative Law Judge. 

Responses to the complaint and the 

notice of investigation must be 

submitted by the named respondents in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(e) and 210.13(a), as 

amended in 85 FR 15798 (March 19, 

2020), such responses will be 

considered by the Commission if 

received not later than 20 days after the 

date of service by the complainant of the 

complaint and the notice of 

investigation. Extensions of time for 

submitting responses to the complaint 

and the notice of investigation will not 

be granted unless good cause therefor is 

shown. 

Failure of a respondent to file a timely 

response to each allegation in the 

complaint and in this notice may be 

deemed to constitute a waiver of the 

right to appear and contest the 

allegations of the complaint and this 

notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the complaint and this notice 

and to enter an initial determination 

and a final determination containing 

such findings, and may result in the 

issuance of an exclusion order or a cease 

and desist order or both directed against 

the respondent. 

By order of the Commission. 

Issued: August 31, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–19165 Filed 9–3–21; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation Nos. 701–TA–662 and 731– 

TA–1554 (Final)] 

Pentafluoroethane (R–125) From 

China; Scheduling of the Final Phase 

of Countervailing Duty and AntiDumping Duty Investigations 

AGENCY: United States International 

Trade Commission. 

ACTION: Notice. 

SUMMARY: The Commission hereby gives 

notice of the scheduling of the final 

phase of antidumping and 

countervailing duty investigation Nos. 

701–TA–662 and 731–TA–1554 (Final) 

pursuant to the Tariff Act of 1930 (‘‘the 

Act’’) to determine whether an industry 

in the United States is materially 

injured or threatened with material 

injury, or the establishment of an 

industry in the United States is 

materially retarded, by reason of 

imports of pentafluoroethane (R–125) 

from China, provided for in subheadings 

2903.39.20 and 2903.39.29 of the 

Harmonized Tariff Schedule of the 

United States, preliminarily determined 

by the Department of Commerce 

(‘‘Commerce’’) to be subsidized and sold 

at less-than-fair-value. 

DATES: August 17, 2021. 

FOR FURTHER INFORMATION CONTACT: 

Ahdia Bavari ((202) 205–3191), Office of 

Investigations, U.S. International Trade 

Commission, 500 E Street SW, 

Washington, DC 20436. 

Hearing-impaired persons can obtain 

information on this matter by contacting 

the Commission’s TDD terminal on 202– 

205–1810. Persons with mobility 

impairments who will need special 

assistance in gaining access to the 

Commission should contact the Office 

of the Secretary at 202–205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server (https://

www.usitc.gov). The public record for 

these investigations may be viewed on 

the Commission’s electronic docket 

(EDIS) at https://edis.usitc.gov. 

SUPPLEMENTARY INFORMATION: 

Scope.—For purposes of these 

investigations, Commerce has defined 

the subject merchandise as 

‘‘pentafluoroethane (R–125), or its 

chemical equivalent, regardless of form, 

type or purity level. R–125 has the 

Chemical Abstracts Service (CAS) 

registry number of 354–33–6 and the 

chemical formula C2HF5. R–125 is also 

referred to as Pentafluoroethane, 

Genetron HFC 125, Khladon 125, Suva 

125, Freon 125, and Fc-125. R–125 that 

has been blended with other products is 

included within the scope if such 

blends contain 85% or more by volume 

R–125, on an actual percentage basis. 

However, R–125 incorporated into a 

blend that conforms to ANSI/ASHRAE 

Standard 34 is excluded from the scope 

of these investigations. When R–125 is 

blended with other products and 

otherwise falls under the scope of these 

investigations, only the R–125 

component of the mixture is covered by 

the scope of these investigations. 

Subject merchandise also includes 

purified and unpurified R–125 that is 

processed in a third country or 

otherwise outside the customs territory 

of the United States, including, but not 

limited to, purifying, blending, or any 

other processing that would not 

otherwise remove the merchandise from 

the scope of these investigations if 

performed in the country of 

manufacture of the in-scope R–125. The 

scope also includes R–125 that is 

commingled with R–125 from sources 

not subject to these investigations. Only 

the subject component of such 

commingled products is covered by the 

scope of these investigations. 

Excluded from the scope is 

merchandise covered by the scope of the 

antidumping order on 

Hydrofluorocarbon Blends from the 

People’s Republic of China, including 


sradovich on DSKJLST7X2PROD with NOTICES
50172 Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices 

merchandise subject to the affirmative 

anti-circumvention determination in 

Hydrofluorocarbon Blends from the 

People’s Republic of China: Affirmative 

Final Determination of Circumvention 

of the Antidumping Duty Order; 

Unfinished R–32/R–125 Blends, 85 FR 

15428 (March 18, 2020). See 

Hydrofluorocarbon Blends from the 

People’s Republic of China: 

Antidumping Duty Order, 81 FR 55436 

(August 19, 2016) (the Blends Order). 

R–125 is entered under Harmonized 

Tariff Schedule of the United States 

(HTSUS) subheading 2903.39.2035 and 

2903.39.2938. Merchandise subject to 

the scope may also be entered under 

HTSUS subheadings 2903.39.2045, 

3824.78.0020, and 3824.78.0050. The 

HTSUS subheadings and CAS registry 

number are provided for convenience 

and customs purposes. The written 

description of the scope of these 

investigations is dispositive.’’ 

Background.—The final phase of 

these investigations is being scheduled 

pursuant to sections 705(b) and 731(b) 

of the Tariff Act of 1930 (19 U.S.C. 

1671d(b) and 1673d(b)), as a result of 

affirmative preliminary determinations 

by Commerce that certain benefits 

which constitute subsidies within the 

meaning of § 703 of the Act (19 U.S.C. 

1671b) are being provided to 

manufacturers, producers, or exporters 

in China of pentafluoroethane (r-125), 

and that such products are being sold in 

the United States at less than fair value 

within the meaning of § 733 of the Act 

(19 U.S.C. 1673b). The investigations 

were requested in petitions filed on 

January 12, 2021, by Honeywell 

International, Inc. 

For further information concerning 

the conduct of this phase of the 

investigations, hearing procedures, and 

rules of general application, consult the 

Commission’s Rules of Practice and 

Procedure, part 201, subparts A and B 

(19 CFR part 201), and part 207, 

subparts A and C (19 CFR part 207). 

Participation in the investigations and 

public service list.—Persons, including 

industrial users of the subject 

merchandise and, if the merchandise is 

sold at the retail level, representative 

consumer organizations, wishing to 

participate in the final phase of these 

investigations as parties must file an 

entry of appearance with the Secretary 

to the Commission, as provided in 

§ 201.11 of the Commission’s rules, no 

later than 21 days prior to the hearing 

date specified in this notice. A party 

that filed a notice of appearance during 

the preliminary phase of the 

investigations need not file an 

additional notice of appearance during 

this final phase. The Secretary will 

maintain a public service list containing 

the names and addresses of all persons, 

or their representatives, who are parties 

to the investigations. 

Please note the Secretary’s Office will 

accept only electronic filings during this 

time. Filings must be made through the 

Commission’s Electronic Document 

Information System (EDIS, https://

edis.usitc.gov.) No in-person paperbased filings or paper copies of any 

electronic filings will be accepted until 

further notice. 

Limited disclosure of business 

proprietary information (BPI) under an 

administrative protective order (APO) 

and BPI service list.—Pursuant to 

§ 207.7(a) of the Commission’s rules, the 

Secretary will make BPI gathered in the 

final phase of these investigations 

available to authorized applicants under 

the APO issued in the investigations, 

provided that the application is made 

no later than 21 days prior to the 

hearing date specified in this notice. 

Authorized applicants must represent 

interested parties, as defined by 19 

U.S.C. 1677(9), who are parties to the 

investigations. A party granted access to 

BPI in the preliminary phase of the 

investigations need not reapply for such 

access. A separate service list will be 

maintained by the Secretary for those 

parties authorized to receive BPI under 

the APO. 

Staff report.—The prehearing staff 

report in the final phase of these 

investigations will be placed in the 

nonpublic record on November 30, 

2021, and a public version will be 

issued thereafter, pursuant to § 207.22 of 

the Commission’s rules. 

Hearing.—The Commission will hold 

a hearing in connection with the final 

phase of these investigations beginning 

at 9:30 a.m. on Tuesday, December 14, 

2021. Information about the place and 

form of the hearing, including about 

how to participate in and/or view the 

hearing, will be posted on the 

Commission’s website at https://

www.usitc.gov/calendarpad/ 

calendar.html. Interested parties should 

check the Commission’s website 

periodically for updates. Requests to 

appear at the hearing should be filed in 

writing with the Secretary to the 

Commission on or before Tuesday, 

December 7, 2021. A nonparty who has 

testimony that may aid the 

Commission’s deliberations may request 

permission to present a short statement 

at the hearing. All parties and 

nonparties desiring to appear at the 

hearing and make oral presentations 

should attend a prehearing conference 

to be held at 9:30 a.m. on Thursday, 

December 9, 2021. Oral testimony and 

written materials to be submitted at the 

public hearing are governed by sections 

201.6(b)(2), 201.13(f), and 207.24 of the 

Commission’s rules. Parties must submit 

any request to present a portion of their 

hearing testimony in camera no later 

than 7 business days prior to the date of 

the hearing. 

Written submissions.—Each party 

who is an interested party shall submit 

a prehearing brief to the Commission. 

Prehearing briefs must conform with the 

provisions of § 207.23 of the 

Commission’s rules; the deadline for 

filing is December 7, 2021. Parties may 

also file written testimony in connection 

with their presentation at the hearing, as 

provided in § 207.24 of the 

Commission’s rules, and posthearing 

briefs, which must conform with the 

provisions of § 207.25 of the 

Commission’s rules. The deadline for 

filing posthearing briefs is December 21, 

2021. In addition, any person who has 

not entered an appearance as a party to 

the investigations may submit a written 

statement of information pertinent to 

the subject of the investigations, 

including statements of support or 

opposition to the petition, on or before 

December 21, 2021. Parties may submit 

supplemental comments on Commerce’s 

final countervailing and antidumping 

duty determinations on or before 

January 7, 2022. Supplemental party 

comments may address only 

Commerce’s final determinations and 

may not exceed five (5) pages in length. 

On January 26, 2022, the Commission 

will make available to parties all 

information on which they have not had 

an opportunity to comment. Parties may 

submit final comments on this 

information on or before January 28, 

2022, but such final comments must not 

contain new factual information and 

must otherwise comply with § 207.30 of 

the Commission’s rules. All written 

submissions must conform with the 

provisions of § 201.8 of the 

Commission’s rules; any submissions 

that contain BPI must also conform with 

the requirements of §§ 201.6, 207.3, and 

207.7 of the Commission’s rules. The 

Commission’s Handbook on Filing 

Procedures, available on the 

Commission’s website at https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf, elaborates 

upon the Commission’s procedures with 

respect to filings. 

Additional written submissions to the 

Commission, including requests 

pursuant to § 201.12 of the 

Commission’s rules, shall not be 

accepted unless good cause is shown for 

accepting such submissions, or unless 

the submission is pursuant to a specific 

request by a Commissioner or 

Commission staff. 


sradovich on DSKJLST7X2PROD with NOTICES
Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices 50173 

1MLP means Mid-Level Practitioner. 21 CFR 

1300.01(b). 

In accordance with §§ 201.16(c) and 

207.3 of the Commission’s rules, each 

document filed by a party to the 

investigations must be served on all 

other parties to the investigations (as 

identified by either the public or BPI 

service list), and a certificate of service 

must be timely filed. The Secretary will 

not accept a document for filing without 

a certificate of service. 

Authority: These investigations are 

being conducted under authority of title 

VII of the Tariff Act of 1930; this notice 

is published pursuant to § 207.21 of the 

Commission’s rules. 

By order of the Commission. 

Issued: September 1, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–19316 Filed 9–3–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Uvienome Linda Sakor, N.P.; Decision 

and Order 

I. Introduction 

On June 19, 2019, the Assistant 

Administrator, Diversion Control 

Division, Drug Enforcement 

Administration (hereinafter, DEA or 

Government), issued an Order to Show 

Cause (hereinafter, OSC) to Uvienome 

Sakor, N.P., also known as Uvienome 

Linda Sakor, N.P., (hereinafter, 

Respondent) of Douglasville, Georgia. 

OSC, at 1. The OSC proposed the 

revocation of Respondent’s Certificate of 

Registration No. MS1972101, the denial 

of any pending applications for renewal 

or modification of that registration, and 

the denial of any applications for 

additional DEA registrations for two 

reasons. Id. First, it alleged that 

Respondent ‘‘materially falsified 

multiple renewal applications . . . filed 

with the DEA.’’ Id. (citing 21 U.S.C. 

824(a)(1)). Second, it alleged that 

Respondent ‘‘pled guilty to a felony 

relating to controlled substances.’’ OSC, 

at 1 (citing 21 U.S.C. 824(a)(2)). 

Specifically, the OSC alleged that 

Respondent entered a guilty plea in 

Georgia Superior Court to one count of 

Forgery in the First Degree ‘‘for 

attempting to fill a forged controlled 

substance prescription.’’ OSC, at 2. This 

OSC allegation acknowledged that, 

under Georgia’s First Offender Act, 

Respondent was discharged from 

probation, was exonerated of any 

criminal purpose, and is not considered 

to have a criminal conviction. Id. 

Second, the OSC alleged that 

Respondent entered into a Consent 

Order with the Georgia Board of Nursing 

(hereinafter, GBN) for her failure to 

report her Forgery guilty plea as 

required by Georgia statute. Id. It also 

alleged that the Consent Order placed 

Respondent on probation for two years. 

Id. 

Third, the OSC alleged that 

Respondent submitted three materially 

false registration renewal applications 

after her guilty plea because she did not 

respond affirmatively to the first 

Liability question. Id. at 2–3. Similarly, 

the OSC alleged that Respondent 

submitted two materially false 

registration renewal applications after 

the beginning of the Consent Order’s 

probationary period because she did not 

respond affirmatively to the third 

Liability question. Id. at 3. 

Fourth, the OSC alleged that 

Respondent’s guilty plea to the state 

Forgery charge implicates 21 U.S.C. 

824(a)(2). Id. 

The OSC notified Respondent of the 

right to request a hearing on the 

allegations or to submit a written 

statement, while waiving the right to a 

hearing, the procedures for electing each 

option, and the consequences for failing 

to elect either option. Id. at 4 (citing 21 

CFR 1301.43). The OSC also notified 

Respondent of the opportunity to 

submit a corrective action plan. OSC, at 

4–5 (citing 21 U.S.C. 824(c)(2)(C)). 

The Government forwarded its 

Request for Final Agency Action 

(hereinafter, RFAA), along with the 

evidentiary record, to this office on 

September 5, 2019. Attached to the 

RFAA is the Declaration of a DEA 

Diversion Investigator (hereinafter, DI) 

that is signed and sworn to under 

penalty of perjury. RFAA Exhibit 

(hereinafter, RFAAX) 6 (Declaration of 

Diversion Investigator, dated September 

5, 2019 (hereinafter, DI Declaration)). 

The DI Declaration states that the DI 

‘‘personally served’’ the OSC on 

Respondent at her registered location on 

June 24, 2019. Id. at 3. I credit the DI’s 

sworn statement. 

Respondent waived her right to a 

hearing and filed a written statement. 

RFAAX 3 (Respondent’s Written 

Statement, dated July 17, 2019 

(hereinafter, Written Statement)), at 1. 

Her Written Statement explicitly 

references the OSC. Id. 

Based on all of the evidence in the 

record, I find that the Government’s 

service of the OSC was legally 

sufficient. In addition, based on all of 

the evidence in the record, I find that 

Respondent timely filed her Written 

Statement. 21 CFR 1301.43. 

I issue this Decision and Order based 

on the Government’s submission, which 

includes the Written Statement, and is 

the entire record before me. 21 CFR 

1301.43(e). 

II. Findings of Fact 

A. Respondent’s DEA Controlled 

Substance Registration 

Respondent is the holder of DEA 

Certificate of Registration No. 

MS1972101 at the registered address of 

6559 Church St., Douglasville, GA 

30134–1885. RFAAX 1 (Certification of 

Registration History, dated September 4, 

2019), at 1. Pursuant to this registration, 

Respondent is authorized to dispense 

controlled substances in schedules III 

through V as a MLP-nurse 

practitioner.1 Id. Respondent’s 

registration expired on February 28, 

2021, and is in an ‘‘active pending 

status.’’ Id. 

B. The Investigation of Respondent 

According to the DI assigned to this 

matter, ‘‘a large number of prescriptions 

that had been issued by . . . 

[Respondent] had been filled’’ at a 

pharmacy the DI was investigating, and 

Respondent is the sister of the 

pharmacy’s owner. RFAAX 6, at 1. The 

DI Declaration states that Respondent 

‘‘previously had been convicted of a 

felony involving forgery and that her 

nursing license had been placed on 

probation.’’ Id. According to the DI 

Declaration, the DI’s investigation 

included obtaining certified copies of 

records of the Superior Court of Douglas 

County and of the GBN. Id. at 2; see also 

infra section II.C. 

C. The Government’s Case 

The Government’s case includes five 

exhibits, one of which is the Written 

Statement. 

The first exhibit is the Certification of 

Registration History. RFAAX 1. 

According to that Certification, 

Respondent submitted to the Agency 

registration renewal applications on 

December 31, 2011, February 25, 2015, 

and January 5, 2018. Id. at 1. On each 

of the three submissions, the 

Certification of Registration History 

states, Respondent answered ‘‘No’’ to 

whether she ‘‘has . . . ever been 

convicted of a crime in connection with 

controlled substance(s) under state or 

federal law, . . . or any such action 

pending.’’ Id. at 1–2, 4, 7, 10. Further, 

on each of the three submissions, 

according to the Certification of 

Registration History, Respondent 

answered ‘‘No’’ to whether she ‘‘has 


sradovich on DSKJLST7X2PROD with NOTICES